Nasogastric lansoprazole is effective in suppressing gastric acid secretion in critically ill patients

Alimentary Pharmacology and Therapeutics

Volumn 14, Issue 1, 2000, Pages 123-127

  Tsai, W L ^a   Poon, S K ^a   Yu, H K ^a   Chang, C S ^a   Yeh, H Z ^a   Ko, C W ^a   Chen, G H ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; RANITIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CRITICAL ILLNESS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; MALE; NASOGASTRIC TUBE; PRIORITY JOURNAL; STOMACH ACID SECRETION; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; CRITICAL ILLNESS; ENZYME INHIBITORS; FEMALE; GASTRIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; INTUBATION, GASTROINTESTINAL; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; TIME FACTORS;

EID: 0033984049     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2000.00680.x     Document Type: Article

References (28)

1. 1 Peura DA, Johnson LF. Ciractidinc for prevention and treatment of gastroduodenal mucosal lesions in patients in an intensive care unit. Ann Intern Med 1985; 103: 173-7.
2. 2 Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med 1994; 330: 377-81.
3. 3 Ben-Menachen T, Fogel R. Patel RV, et al. Prophylaxis for stress related gastric hemorrhage in the medical intensive care unit: a randomized controlled single blind study. Ann Intern Med 1994; 121: 568-75.
4. 4 Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients: resolving discordant meta-analyses. J Am Med Assoc 1996; 275: 308-14.
5. 5 Wilcox CM, Spenney JG. Stress ulcer prophylaxis in medical patients: who, what, and how much? Am J Gastroenterol 1988; 83: 1199-211.
6. 6 Pilbrant A, Cederberg C. Development of an oral formulation of omeprazole. Scand J Gastroenterol 1985; 20(Suppl. 108): 113-20.
7. 7 Knaus WA, Draper EA, Wagner DP, Zimmerman JE. Apache II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
8. 8 Cook DJ. Witt LG, Cook RJ. Guyatt GH. Stress ulcer prophylaxis in the critically ill: a meta-analysis. Am J Med 1991; 91: 519-27.
9. 9 Martin LF, Booth FV, Karlstadt RG. et ill Continuous intravenous cimetidine decreased stress-related upper gastrointestinal hemorrhage without promoting pneumonia. Crit Care Med 1993; 21: 19-30.
10. 10 Siepler JK. A dosage alternative for H2-receptor antagonists: constant infusion. Clin Ther 1986; 8(Suppl. A): 24-33.
11. 11 Ballesteros MA, Hogan DL, Koss MA, Isenberg JI. Bolus or intravenous infusion of ranitidine: effects on gastric pH and acid secretion: a comparison of relative cost and efficacy. Ann Intern Med 1990; 112: 334-9.
12. 12 Burgess P, Larson CM, Davidson P, Brown J, Metz CA. Effect of ranitidine on intragastric pit and stress related upper gastrointestinal bleeding in patients with severe head injury. Dig Dis Sci 1995; 40: 645-50.
13. 13 Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing. Gastroenterology 1994; 106: 60-4.
14. 14 Holt S, Howden CW. Omeprazole: overview and opinion. Dig Dis Sci 1991; 36: 385-93.
15. 15 Balaban DH, Duckworlh CW, Peura DA. Nasogastric omeprazole: effects on gastric pH in critically ill patients. Am J Gastroenterol 1997; 92: 79-83.
16. 16 Phillips JO, Metzler MH, Palmieri MTL, Huckfeldt RE, Dahl NG. A prospective study of simplified omeprazole suspension for the prophylaxis of stress-related mucosal damage. Crit Care Med 1996; 24: 1793-800.
17. 17 Lasky MR, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma 1998; 44: 527-33.
18. 18 Sharma VK, Vasudeva R, Howden CW. Simplified lansoprazole suspension - a liquid formulation of lansoprazole - effectively suppresses intragastric acidity when administered through a gastrostomy. Am J Gastroenterol 1999; 94: 181 3-17.
19. 19 Howden CW, Forrest JAH, Reid JL. Effect of single and repeated doses of omeprazole on gastric acid and pepsin secretion in man. Gut 1985; 88: 64-9.
20. 20 Howden CW, Meredith PA, Forrest JAH, Reid JL. Oral pharmacokinetics of omeprazole. Eur J Clin Pharmacol 1994; 26: 641-3.
21. 21 Ashida K, Sakaguchi M, Tanaka M, Takiuchi H, Egashira Y, Katsu K. Clinical study on the pathophysiology and treatment of PPI-resistant ulcers. J Clin Gastroenterol 1995; 20(Suppl. 2): S67-71.
22. 22 Hase T, Anderson PR, Mehlmann P. Significance of gastric secretory changes in pathogencsis of stress ulcers. Dig Dis Sci 1975; 20: 443-9.
23. 23 Stannard VA, Hutchinson A, Morris DL, Byrne A. Gastric exocrine 'failure' in critically ill patients: incidence and associated features. Br Med J 1988; 296: 155-6.
24. 24 Gonzalez ER. Pathophysiologic changes in the critically ill patients: risk factors for ulceration and altered drug metabolism. DICP 1990; 24(Suppl. 11): S5-7.
25. 25 Sharma BK, Walt RP, Pounder RE, Gomes MDFA, Wood EC, Logan LH. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut 1984; 25: 957-64.
26. 26 Howden CW, Forrest JAH, Meredith PA, Reid JL. Anti-secretory effect and oral pharmacokinetics following low dose omcprazole in man. Br J Clin Pharmacol 1985; 20: 137-9.
27. 27 Hatlebakk JG, Berstad A. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin Pharmacokinet 1996; 31: 386-406.
28. 28 Blum RA, Hunt RH, Kidd SL, Shi H, Jennings DE, Greski-Rose PA. Dose-response relationship of lansoprazole to gastric acid anti-secretory effects. Aliment Pharmacol Ther 1998; 12: 321-7.